Studies indicate that IL‐10 can safeguard against kidney damage caused by ischemia, cisplatin, or ureteral obstruction by curbing the generation of inflammatory cytokines and the penetration of immune cells,[136, 137] suggesting that IL‐10 is a potential therapeutic approach to overcome present clinical difficulties in AKI management. Here, IL10 is linked to Ureteral obstruction.